article Open AccessTop 1% cited
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Breast Cancer Research and Treatment · 2008 · Vol. 115(2) · pp. 359–363
Tomasz Byrski✉(Pomeranian Medical University)Tomasz Huzarski(Pomeranian Medical University)Rebecca Dent(Sunnybrook Health Science Centre)Jacek Gronwald(Pomeranian Medical University)Dorota Zuziak(Lublin Oncology Center)Cezary Cybulski(Pomeranian Medical University)Józef Kładny(Pomeranian Medical University)Bohdan Górski(Pomeranian Medical University)Jan Lubiński(Pomeranian Medical University)Steven A. Narod(Women's College Hospital)
Abstract
Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.
BRCA gene mutations in cancerBreast Cancer Treatment StudiesDNA Repair MechanismsBreast cancerMedicineOncologyChemotherapyInternal medicineMastectomyCisplatinNeoadjuvant therapyCancerClinical trial
MeSH terms
AdultAntineoplastic AgentsBreast NeoplasmsCisplatinFemaleHumansMastectomyMiddle AgedMutationGenetic Predisposition to DiseaseNeoadjuvant TherapyUbiquitin-Protein Ligases
Citations
339
FWCI
18.11
field-weighted impact
References
19
Percentile
99%
vs. same field & year
Citations per year
Cited by
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Clinical Cancer Research · 2016 · 1,128 citations
References
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Journal of Clinical Oncology · 2008 · 2,876 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.